Oppenheimer Maintains Acadia Pharmaceuticals (ACAD) Perform Recommendation
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
Fintel reports that on July 14, 2023, Oppenheimer maintained coverage of Acadia Pharmaceuticals (NASDAQ:ACAD) with a Perform recommendation. Analyst Price Forecast Suggests 2.06% Downside
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1245836826-2b88234057c442f7bf5538ddb7f7584a.jpg "What It Would Take for the U.S. Dollar To Collapse")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1336655800-0cde652f461b4771aa45601032b5420b.jpg "Home Equity Loans and Divorce")
:max_bytes(150000):strip_icc():format(jpeg)/WhatIstheThree-YearRuleAug.262021-09d1295e78a743ecac4a31c6c042d52d.jpg "Reverse Mortgage Income Requirements")